Description Usage Arguments Details Value Author(s) References See Also Examples

View source: R/refinedBoundaries.R

Refined secondary boundaries, and nominal significance for the secondary endpoint are calculated.

1 2 |

`alpha` |
type I error probability. |

`tVec` |
vector of relative information levels. The last element in the vector is 1. |

`pOBF` |
type of primary boundary, |

`sOBF` |
type of secondary boundary, |

`LanDeMets` |
type of boundary, |

`nRepVec` |
computing paramter, number of replica, a vector of four numbers. |

`initIntvl` |
computing paramter, a pair of numbers containing the end-points of the interval to be searched for the root. |

This function gives a list including refined secondary boundary and the nominal significance for the secondary endpoint.
There are two computing parameters `nRepVec`

and `initIntvl`

. Parameter `nRepVec`

includes four numbers:
`nRepVec[1]`

is the number of replica for calculating primary boundaries,
`nRepVec[2]`

is the number of replica for searching the location of peak,
`nRepVec[3]`

is the number of replica for calculating secondary boundaries,
`nRepVec[4]`

is the number of replica for calculating the nominal significance.
Parameter `initIntvl`

contains the end-points of the interval to be searched for the root.
For Lan-DeMets error spending approach, the lower end point should choose a number slightly less than 1,
and the upper end point should choose a number between 4 and 10.

a result list including refined secondary boundary and the nominal significance for the secondary endpoint.

Jiangtao Gou

Glimm, E., Maurer, W., and Bretz, F. (2010). Hierarchical testing of multiple endpoints in group-sequential trials. *Statistics in Medicine* **29**, 219-228.

Hung, H. M. J., Wang, S.-J., and O'Neill, R. (2007). Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. *Journal of Biopharmaceutical Statistics* **17**, 1201-1210.

Jennison, C. and Turnbull, B. W. (2000). *Group Sequential Methods with Applications to Clinical Trials*. Chapman and Hall/CRC, New York.

Lan, K. K. G., and Demets, D. L. (1983). Discrete sequential boundaries for clinical trials. *Biometrika* **70**, 659-663.

O'Brien, P. C., and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. *Biometrics* **35**, 549-556.

Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. *Biometrika* **64**, 191-199.

Tamhane, A. C., Mehta, C. R., and Liu, L. (2010). Testing a primary and a secondary endpoint in a group sequential design. *Biometrics* **66**, 1174-1184.

Tamhane, A. C., Gou, J., Jennison, C., Mehta, C. R., and Curto, T. (2017+). A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks. *Biometrics*, to appear.

`secondaryBoundaryVecLD`

, `secondaryBoundaryVecOrig`

1 2 3 4 5 6 | ```
#require(mvtnorm)
#require(ldbounds)
#result <- secondaryBoundaryVec(alpha=0.025,tVec=c(1/2,1),pOBF=TRUE,sOBF=FALSE,
# LanDeMets=FALSE,nRepVec=c(1,1,1,1),initIntvl=c(0.8,5))
#result$secondaryBoundary
#result$nomialSignificance
``` |

gsrsb documentation built on May 29, 2017, 7:12 p.m.

Embedding an R snippet on your website

Add the following code to your website.

For more information on customizing the embed code, read Embedding Snippets.